Pharmacological interventions for social cognitive impairments in schizophrenia: A systematic review and network meta-analysis of randomized controlled trials
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Social cognitive impairments are a fundamental aspect of schizophrenia, exerting a substantial influence on patients' functional outcomes. However, to date, there have been no meta-analyses of comprehensive pharmacological interventions covering all domains of social cognition. The aim of the present study was to address this knowledge gap by conducting a network meta-analysis, a comprehensive approach that systematically compares the efficacy of pharmacological interventions across all domains of social cognition. METHODS: A literature search for randomized controlled trials (RCTs) was conducted using PubMed, Embase, the Cochrane Central Register of Controlled Trials, PsycINFO, ClinicalTrials.gov, and the International Clinical Trials Registry Platform. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. RESULTS: A total of 8,752 records were screened, and 60 RCTs involving 4,270 subjects were included in the systematic review. Thirty-six pharmacological interventions were extracted, but no compounds had a significant ameliorative effect on social cognition in comparison with placebo. In each domain of social cognition, the following compounds were identified as the most probable candidates for treatment selection: selective glycine uptake inhibitor (standardized mean difference [SMD], 0.46; 95% credible interval [CI], -0.52 to 1.44) and stimulant (SMD, 0.44; 95% CI, -0.57 to 1.45) for emotion perception in comparison with placebo. In the context of emotion processing, γ-aminobutyric acid (A) α2/α3 partial agonist (SMD, 0.33; 95% CI, -0.53 to 1.19) emerged as the top compound. CONCLUSIONS: To date, no pharmacological interventions have demonstrated efficacy for social cognitive impairments in schizophrenia.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Pharmacological interventions for social cognitive impairments in schizophrenia: A systematic review and network meta-analysis of randomized controlled trials
- Date Crossref
- 01/01/2026
- Éditeur
- Royal College of Psychiatrists
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Center of Neurology and Psychiatry pays non établi dans la noticeÉtablissement de santé
-
Soseikai General Hospital pays non établi dans la noticeÉtablissement de santé
-
Keio University pays non établi dans la noticeUniversité ou école supérieure
-
Hokkaido University pays non établi dans la noticeUniversité ou école supérieure
-
Toho University pays non établi dans la noticeUniversité ou école supérieure
-
Fukushima Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Hokkaido University Hospital pays non établi dans la noticeÉtablissement de santé
-
Musashino University pays non établi dans la noticeUniversité ou école supérieure
-
Fukushima Medical Center of Mental Health pays non établi dans la noticeÉtablissement de santé
National Center of Neurology and Psychiatry, Soseikai General Hospital et Keio University, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.